Tisdag 3 Mars | 13:41:06 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

SynAct Pharma secures 51,9 million SEK to strengthen clinical runway
2026-03-03 08:43:00

SynAct Pharma has successfully carried out a directed share issue of approximately 51,9 million SEK to Swedish and international qualified investors. This secures a stronger financial platform as the it enters a transformational phase, providing negotiating leverage ahead of upcoming partnering discussions following the data readouts for resomelagon in rheumatoid arthritis and viral-induced inflammation. BioStock contacted CEO Jeppe Øvlesen for a comment.

Read the full interview at biostock.se:

SynAct Pharma secures SEK 51,9 million ahead of clinical milestones
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden